New Zealand markets closed

Poseida Therapeutics, Inc. (PSTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.1900+0.1100 (+3.57%)
At close: 04:00PM EDT
3.1800 -0.01 (-0.31%)
After hours: 07:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.0800
Open3.1000
Bid3.1700 x 200
Ask3.2100 x 300
Day's range3.0200 - 3.2400
52-week range1.5400 - 4.2700
Volume689,878
Avg. volume748,396
Market cap307.8M
Beta (5Y monthly)0.39
PE ratio (TTM)N/A
EPS (TTM)-1.3700
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.00
  • PR Newswire

    Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024. Dr. Rizvi is a seasoned executive with over 20 years of experience across all stages of drug development, including clinical strategy, execution, and commercialization.

  • PR Newswire

    Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, 2024 at 1:00pm PT | 4:00pm ET.

  • PR Newswire

    Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma

    Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate. The Company is investigating P-BCMA-ALLO1 in partnership with